Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipatasertib + Atezolizumab + Paclitaxel in TNBC (IPATunity170)
NCT04177108Phase 3Completed
- Sponsor
- Roche
- Start
- Nov 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 37
01
Overview
Phase 3, randomised, double-blind trial of ipatasertib in triple-negative breast cancer (TNBC) (5 arms), sponsored by Roche. Primary endpoints: Progression-Free Survival at 39 months and Overall Survival at 39 months. Started Nov 2019; status: completed.
02
Drugs
ipatasertib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04177108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04177108.